| __timestamp | Alnylam Pharmaceuticals, Inc. | Gilead Sciences, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 44526000 | 2983000000 |
| Thursday, January 1, 2015 | 60610000 | 3426000000 |
| Friday, January 1, 2016 | 89354000 | 3398000000 |
| Sunday, January 1, 2017 | 199365000 | 3878000000 |
| Monday, January 1, 2018 | 382359000 | 4056000000 |
| Tuesday, January 1, 2019 | 479005000 | 4381000000 |
| Wednesday, January 1, 2020 | 588420000 | 5151000000 |
| Friday, January 1, 2021 | 620639000 | 5246000000 |
| Saturday, January 1, 2022 | 770658000 | 5673000000 |
| Sunday, January 1, 2023 | 795646000 | 6090000000 |
| Monday, January 1, 2024 | 975526000 | 6091000000 |
In pursuit of knowledge
In the competitive landscape of the pharmaceutical industry, understanding the financial strategies of leading companies is crucial. Over the past decade, Gilead Sciences, Inc. and Alnylam Pharmaceuticals, Inc. have shown distinct trends in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Gilead's SG&A expenses have consistently been higher, peaking at approximately $6.09 billion in 2023, reflecting a 104% increase from 2014. In contrast, Alnylam's expenses grew more dramatically, surging by over 1,600% to nearly $796 million in the same period. This stark difference highlights Gilead's established market presence and Alnylam's aggressive growth strategy. As these companies navigate the evolving pharmaceutical landscape, their SG&A trends offer valuable insights into their operational priorities and market strategies.
AstraZeneca PLC and Alnylam Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Cost Management Insights: SG&A Expenses for Gilead Sciences, Inc. and Genmab A/S
SG&A Efficiency Analysis: Comparing Gilead Sciences, Inc. and MorphoSys AG
Operational Costs Compared: SG&A Analysis of Gilead Sciences, Inc. and Veracyte, Inc.
Operational Costs Compared: SG&A Analysis of Gilead Sciences, Inc. and Iovance Biotherapeutics, Inc.
Comparing SG&A Expenses: Vertex Pharmaceuticals Incorporated vs Alnylam Pharmaceuticals, Inc. Trends and Insights
Breaking Down SG&A Expenses: GSK plc vs Alnylam Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Alnylam Pharmaceuticals, Inc. and Exelixis, Inc.
Selling, General, and Administrative Costs: Alnylam Pharmaceuticals, Inc. vs CymaBay Therapeutics, Inc.
Selling, General, and Administrative Costs: Alnylam Pharmaceuticals, Inc. vs Grifols, S.A.
SG&A Efficiency Analysis: Comparing Alnylam Pharmaceuticals, Inc. and Soleno Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for Alnylam Pharmaceuticals, Inc. and Taro Pharmaceutical Industries Ltd.